A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Summary

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

Interventions

• Palliative radiotherapy · RADIATION

  Palliative radiotherapy (RT) will be performed using external beam ionizing radiation in accordance with standard practice

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines.
* Age ≥ 18 years
* ECOG Performance Status of 0 or 1.

Exclusion Criteria:

* Patients who are pregnant or breastfeeding
* Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed).
* Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
* Patients with a "currently active" metastatic second malignancy.
* Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study.
* Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities.
* Unwilling or unable to participate in all required study evaluations and procedures.
* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Sites (7)

• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey · RECRUITING
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey · RECRUITING
• Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey · RECRUITING
• Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York · RECRUITING
• Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York · RECRUITING
• Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York · RECRUITING
• Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York · RECRUITING